Clinical Trial Update: A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant [Phase 2]

View source ↗

Summary

Phase 2 pre-surgical pharmacokinetic study of intramuscular and intraductal fulvestrant in female breast cancer settings has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ
• Female Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)

Snippet

Sponsor: Atossa Therapeutics, Inc. | Conditions: Female Breast Carcinoma, Female Ductal Carcinoma In Situ | Phase 2 | Status: TERMINATED | Results posted: 2022-04-05